Leprosy: The age-old companion of humans - Re-evaluation and comparative analysis of Avar-period cases with Hansen's disease from the Danube-Tisza Interfluve, Hungary

Tuberculosis (Edinb). 2023 Sep:142:102393. doi: 10.1016/j.tube.2023.102393. Epub 2023 Sep 1.

Abstract

In recent years, our knowledge of leprosy in the past has substantially been enriched. Nonetheless, much still remains to be discovered, especially in regions and periods from where no written sources are available. To fill in some research gaps, we provide the comparative analysis of eight Avar-period leprosy cases from the Danube-Tisza Interfluve (Hungary). In every case, to reconstruct the biological consequences of leprosy, the detected bony changes were linked with palaeopathological and modern medical information. To reconstruct the social consequences of being affected by leprosy, conceptualisation of the examined individuals' treatment in death was conducted. In every case, the disease resulted in deformation and disfigurement of the involved anatomical areas (rhinomaxillary region, feet, and/or hands) with difficulties in conducting certain physical activities. These would have been disadvantageous for the examined individuals and limited or changed their possibilities to participate in social situations. The most severe cases would have required continuous support from others to survive. Our findings indicate that, despite their very visible disease and associated debility, the examined communities did not segregate leprosy sufferers but provided and cared for them, and maintained a strong enough social network that made their survival possible even after becoming incapable of self-sufficiency.

Keywords: Avar period; Danube-Tisza Interfluve; Leprosy; Macromorphological disease manifestations; Palaeopathology; Social stigma.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Evidence Gaps
  • Humans
  • Hungary
  • Leprosy* / diagnosis
  • Leprosy* / drug therapy
  • Mycobacterium tuberculosis*
  • Sulfacetamide

Substances

  • Sulfacetamide